Glypican-1 antisense transfection modulates TGF-β-dependent signaling in Colo-357 pancreatic cancer cells

Biochemical and Biophysical Research Communications

Volumn 320, Issue 4, 2004, Pages 1148-1155

  Li, Junsheng ^a   Kleeff, Jörg ^a   Kayed, Hany ^a   Felix, Klaus ^a   Penzel, Roland ^a   Büchler, Markus W ^a   Korc, Murray ^b   Friess, Helmut ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Glypican; Heparansulfate; Pancreatic cancer; Proteoglycans; TGF

Indexed keywords

COMPLEMENTARY DNA; GLYPICAN; GLYPICAN 1; PROTEIN P21; PROTEOHEPARAN SULFATE; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ASSAY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ASSAY; GENE CONSTRUCT; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MECHANOTRANSDUCTION; NITROBLUE TETRAZOLIUM TEST; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS REGULATION;

CELL DIVISION; CELL LINE, TUMOR; DNA, ANTISENSE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 3142693322     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.06.063     Document Type: Article

References (44)

1. Nakato H., Futch T.A., Selleck S.B. The division abnormally delayed (dally) gene: a putative integral membrane proteoglycan required for cell division patterning during postembryonic development of the nervous system in Drosophila. Development. 121:1995;3687-3702
2. Baeg G.H., Lin X., Khare N., Baumgartner S., Perrimon N. Heparan sulfate proteoglycans are critical for the organization of the extracellular distribution of Wingless. Development. 128:2001;87-94
3. Filmus J., Selleck S.B. Glypicans: proteoglycans with a surprise. J. Clin. Invest. 108:2001;497-501
4. Fukuda K., Inui Y., Kawata S., Higashiyama S., Matsuda Y., Maeda Y., Igura T., Yoshida S., Taniguchi N., Matsuzawa Y. Increased mitogenic response to heparin-binding epidermal growth factor-like growth factor in vascular smooth muscle cells of diabetic rats. Arterioscler. Thromb. Vasc. Biol. 15:1995;1680-1687
5. Sakata H., Stahl S.J., Taylor W.G., Rosenberg J.M., Sakaguchi K., Wingfield P.T., Rubin J.S. Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms. Heparan sulfate glycosaminoglycan requirement for Met binding and signaling. J. Biol. Chem. 272:1997;9457-9463
6. Itoh K., Sokol S.Y. Heparan sulfate proteoglycans are required for mesoderm formation in Xenopus embryos. Development. 120:1994;2703-2711
7. Reichsman F., Smith L., Cumberledge S. Glycosaminoglycans can modulate extracellular localization of the wingless protein and promote signal transduction. J. Cell Biol. 135:1996;819-827
8. Lin X., Perrimon N. Role of heparan sulfate proteoglycans in cell-cell signaling in Drosophila. Matrix Biol. 19:2000;303-307
9. Jackson S.M., Nakato H., Sugiura M., Jannuzi A., Oakes R., Kaluza V., Golden C., Selleck S.B. dally, a Drosophila glypican, controls cellular responses to the TGF-beta-related morphogen, Dpp. Development. 124:1997;4113-4120
10. Kleeff J., Ishiwata T., Kumbasar A., Friess H., Buchler M.W., Lander A.D., Korc M. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J. Clin. Invest. 102:1998;1662-1673
11. Kleeff J., Wildi S., Kumbasar A., Friess H., Lander A.D., Korc M. Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells. Pancreas. 19:1999;281-288
12. Derynck R., Akhurst R.J., Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29:2001;117-129
13. Attisano L., Wrana J.L. Signal transduction by the TGF-beta superfamily. Science. 296:2002;1646-1647
14. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425:2003;577-584
15. Denicourt C., Dowdy S.F. Another twist in the transforming growth factor beta-induced cell-cycle arrest chronicle. Proc. Natl. Acad. Sci. USA. 100:2003;15290-15291
16. Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 113:2003;685-700
17. Hahn S.A., Schutte M., Hoque A.T., Moskaluk C.A., da Costa L.T., Rozenblum E., Weinstein C.L., Fischer A., Yeo C.J., Hruban R.H., Kern S.E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 271:1996;350-353
18. Kleeff J., Ishiwata T., Maruyama H., Friess H., Truong P., Buchler M.W., Falb D., Korc M. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene. 18:1999;5363-5372
19. Kleeff J., Maruyama H., Friess H., Buchler M.W., Falb D., Korc M. Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem. Biophys. Res. Commun. 255:1999;268-273
20. Wagner M., Kleeff J., Friess H., Buchler M.W., Korc M. Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas. 19:1999;370-376
21. Baldwin R.L., Friess H., Yokoyama M., Lopez M.E., Kobrin M.S., Buchler M.W., Korc M. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int. J. Cancer. 67:1996;283-288
22. Venkatasubbarao K., Ahmed M.M., Mohiuddin M., Swiderski C., Lee E., Gower W.R. Jr., Salhab K.F., McGrath P., Strodel W., Freeman J.W. Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma. Anticancer Res. 20:2000;43-51
23. Friess H., Yamanaka Y., Buchler M., Ebert M., Beger H.G., Gold L.I., Korc M. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology. 105:1993;1846-1856
24. Friess H., Yamanaka Y., Buchler M., Berger H.G., Kobrin M.S., Baldwin R.L., Korc M. Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res. 53:1993;2704-2707
25. Friess H., Kleeff J., Korc M., Buchler M.W. Molecular aspects of pancreatic cancer and future perspectives. Dig. Surg. 16:1999;281-290
26. Liao Q., Guo J., Kleeff J., Zimmermann A., Buchler M.W., Korc M., Friess H. Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology. 124:2003;1830-1845
27. Baldwin R.L., Korc M. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. Growth Factors. 8:1993;23-34
28. Kleeff J., Korc M. Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta1 in COLO-357 cells. J. Biol. Chem. 273:1998;7495-7500
29. Massague J. TGF-beta signal transduction. Annu. Rev. Biochem. 67:1998;753-791
30. Filmus J. Glypicans in growth control and cancer. Glycobiology. 11:2001;19R-23R
31. Midorikawa Y., Ishikawa S., Iwanari H., Imamura T., Sakamoto H., Miyazono K., Kodama T., Makuuchi M., Aburatani H. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int. J. Cancer. 103:2003;455-465
32. Brucato S., Bocquet J., Villers C. Cell surface heparan sulfate proteoglycans: target and partners of the basic fibroblast growth factor in rat Sertoli cells. Eur. J. Biochem. 269:2002;502-511
33. Siegel P.M., Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer. 3:2003;807-821
34. Akhurst R.J., Derynck R. TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol. 11:2001;S44-51
35. Clark R.A., McCoy G.A., Folkvord J.M., McPherson J.M. TGF-beta 1 stimulates cultured human fibroblasts to proliferate and produce tissue-like fibroplasia: a fibronectin matrix-dependent event. J. Cell. Physiol. 170:1997;69-80
36. Villanueva A., Garcia C., Paules A.B., Vicente M., Megias M., Reyes G., de Villalonga P., Agell N., Lluis F., Bachs O., Capella G. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene. 17:1998;1969-1978
37. Paine-Saunders S., Viviano B.L., Zupicich J., Skarnes W.C., Saunders S. Glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev. Biol. 225:2000;179-187
38. Stefansson S., McMahon G.A., Petitclerc E., Lawrence D.A. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr. Pharm. Des. 9:2003;1545-1564
39. Yu L., Hebert M.C., Zhang Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 21:2002;3749-3759
40. Yue J., Frey R.S., Mulder K.M. Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGFbeta. Oncogene. 18:1999;2033-2037
41. Sano Y., Harada J., Tashiro S., Gotoh-Mandeville R., Maekawa T., Ishii S. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling. J. Biol. Chem. 274:1999;8949-8957
42. Bhowmick N.A., Ghiassi M., Aakre M., Brown K., Singh V., Moses H.L. TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc. Natl. Acad. Sci. USA. 100:2003;15548-15553
43. Rowland-Goldsmith M.A., Maruyama H., Matsuda K., Idezawa T., Ralli M., Ralli S., Korc M. Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol. Cancer Ther. 1:2002;161-167
44. Rowland-Goldsmith M.A., Maruyama H., Kusama T., Ralli S., Korc M. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin. Cancer Res. 7:2001;2931-2940